CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 35 enrolled
Drug / intervention
Fostamatinib 100 mg bid and Paclitaxel +2 moredrug
Likely dose
Fostamatinib 100 mg bid and Paclitaxelfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03246074
NCT03246074Phase 1Completed
CompareCT.gov

Phase I Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Aug 11, 2017·Updated Oct 24, 2024

In Brief

A Phase 1 clinical trial evaluating Fostamatinib 100 mg bid and Paclitaxel, Fostamatinib 150 mg bid and Paclitaxel, and 1 other intervention for Ovarian Cancer. Completed, enrolled 35 participants across 3 sites.

Detailed Summary

This research is being done to test the safety of the combination of the study drugs fostamatinib and paclitaxel. This study tests different doses of the drugs to see which doses are safest in people with ovarian cancer when given together.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesUnited States
CollaboratorsRigel Pharmaceuticals, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedAug 11, 2017
Enrollment StartApr 3, 2018
Primary CompletionAug 9, 2022
Study CompletionApr 3, 2023
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 8.9 years ago

Interventions

Fostamatinib 100 mg bid and Paclitaxeldrug

Drug: Fostamatinib (oral; 100 mg bid) Drug: Paclitaxel (60-80 mg/m2)

Fostamatinib 150 mg bid and Paclitaxeldrug

Drug: Fostamatinib (oral; 150 mg bid) Drug: Paclitaxel (60-80 mg/m2)

Fostamatinib 200 mg bid and Paclitaxeldrug

Drug: Fostamatinib (oral; 200 mg bid) Drug: Paclitaxel (60-80 mg/m2)